Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

BACKGROUND: Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. However, the mitogen-activated protein kinase pathway is activated in most melanoma, including BRAF-wt. We assessed whether inhibiting this p...

Descripción completa

Detalles Bibliográficos
Autores principales: Urbonas, V, Schadendorf, D, Zimmer, L, Danson, S, Marshall, E, Corrie, P, Wheater, M, Plummer, E, Mauch, C, Scudder, C, Goff, M, Love, S B, Mohammed, S B, Middleton, M R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386028/
https://www.ncbi.nlm.nih.gov/pubmed/30428063
http://dx.doi.org/10.1093/annonc/mdy500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386028/
https://www.ncbi.nlm.nih.gov/pubmed/30428063
http://dx.doi.org/10.1093/annonc/mdy500

Ejemplares similares